The explanation for this discordance is that both GBMs and low grade gliomas do not demonstrate the more frequently observed and investigated homozygous or deep deletions, rather GBM patients and low grade glioma patients have heterozygous or shallow deletions of ZEB1. In addition, our analysis of glioma patients from our institution through exome sequencing revealed previously unidentified mutations. Here, ZEB1 is linked to central nervous system cancer.